Logo image
Back
Subtle Changes in Endochin-Like Quinolone Structure Alter the Site of Inhibition within the Cytochrome bc(1) Complex of Plasmodium falciparum
Journal article   Open access   Peer reviewed

Subtle Changes in Endochin-Like Quinolone Structure Alter the Site of Inhibition within the Cytochrome bc(1) Complex of Plasmodium falciparum

Allison M. Stickles, Mariana Justino de Almeida, Joanne M. Morrisey, Kayla A. Sheridan, Isaac P. Forquer, Aaron Nilsen, Rolf W. Winter, Jeremy N. Burrows, David A. Fidock, Akhil B. Vaidya, …
Antimicrobial agents and chemotherapy, v 59(4), pp 1977-1982
01 Apr 2015
DOI: https://doi.org/10.1128/AAC.04149-14
PMID: 25605352
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1128/aac.04149-14View
Published, Version of Record (VoR) Open Open Access (License Unspecified)

Abstract

Life Sciences & Biomedicine Pharmacology & Pharmacy Science & Technology Microbiology
The cytochrome bc(1) complex (cyt bc(1)) is the third component of the mitochondrial electron transport chain and is the target of several potent antimalarial compounds, including the naphthoquinone atovaquone (ATV) and the 4(1H)-quinolone ELQ-300. Mechanistically, cyt bc(1) facilitates the transfer of electrons from ubiquinol to cytochrome c and contains both oxidative (Q(o)) and reductive (Q(i)) catalytic sites that are amenable to small-molecule inhibition. Although many antimalarial compounds, including ATV, effectively target the Q(o) site, it has been challenging to design selective Q(i) site inhibitors with the ability to circumvent clinical ATV resistance, and little is known about how chemical structure contributes to site selectivity within cyt bc(1). Here, we used the proposed Q(i) site inhibitor ELQ-300 to generate a drug-resistant Plasmodium falciparum clone containing an I22L mutation at the Q(i) region of cyt b. Using this D1 clone and the Y268S Q(o) mutant strain, P. falciparum Tm90-C2B, we created a structure-activity map of Q(i) versus Q(o) site selectivity for a series of endochin-like 4(1H)-quinolones (ELQs). We found that Q(i) site inhibition was associated with compounds containing 6-position halogens or aryl 3-position side chains, while Q(o) site inhibition was favored by 5,7-dihalogen groups or 7-position substituents. In addition to identifying ELQ-300 as a preferential Q(i) site inhibitor, our data suggest that the 4(1H)-quinolone scaffold is compatible with binding to either site of cyt bc(1) and that minor chemical changes can influence Q(o) or Q(i) site inhibition by the ELQs.

Metrics

6 Record Views
72 citations in Web of Science
67 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs in the Output

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Microbiology
Pharmacology & Pharmacy
Logo image